Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q4 2025 Earnings Presentation
15 slides from Adc Therapeutics Sa's earnings presentation, Mar 10, 2026
Slide 1: 4Q FY 2025 Earnings Call
4Q FY 2025 Earnings Call March 10, 2026
Slide 2: Agenda
Agenda Ameet Mallik 01 Chief Executive Officer Business Update Pepe Carmona Financial Update 02 Chief Financial Officer 03 Q&A 2
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 4: Transformation to a Focused ZYNLONTA-Driven Company
Transformation to a Focused ZYNLONTA-Driven Company § Focused portfolio on hematologic malignancies through ZYNLONTA; discontinued non- Portfolio core solid tumor programs ZYNLONTA § Expanded lifecycle strategy with LOTIS-7 and indolent lymphoma programs and cut Development non-priority studies; adv
Slide 5: ADC Therapeutics Value Creation Horizons and Vision
ADC Therapeutics Value Creation Horizons and Vision Ø Establish ZYNLONTA as backbone therapy with differentiated clinical profile across Horizon 1 Horizon 2 Horizon 3 combinations in 2L+ DLBCL Final Data Approval & Growth Phase Disclosures Compendia Inclusion Ø Provide significant patient benefit in
Slide 6: Key Business Updates
Key Business Updates Commercial § 4Q 2025 net product revenues of $22.3 million as compared to $16.4 million in same quarter 2024 Performance § FY sales remained roughly stable with net revenue of $73.6M compared with $69.3M for FY2024 § LOTIS-5: Phase 3 topline data expected in 2Q 2026, with full d
Slide 7: Advancing ZYNLONTA Development Into 2L+ B-Cell Lymphomas
Advancing ZYNLONTA Development Into 2L+ B-Cell Lymphomas Potential To Move Into 2L+ DLBCL Overall Response Rate Complete Response Rate DLBCL FL MZL LOTIS-5 ZYNLONTA + rituximab1 (N=20) ~80% ~50% 1L LOTIS-7 ZYNLONTA + glofitamab2 ~90% ~78% (N=49) LOTIS-5 2L+ Potential Benefit In Indolent Lymphomas LO
Slide 8: ZYNLONTA U.S. Peak Revenue Potential of $600M-1B
ZYNLONTA U.S. Peak Revenue Potential of $600M-1B ZYNLONTA $600M-1B Peak Revenue in DLBCL & Indolent Lymphomas 2L+ ZYNLONTA plus bispecific LOTIS-7 $500M-800M 2L+ Indolent 2L+ ZYNLONTA plus rituximab lymphomas $200M-300M* $100M-200M LOTIS-5 CURRENT INDICATION 3L+ Monotherapy Peak revenue projection a
Slide 9: Two Distinct Segments in r/r DLBCL Treatment Options
Two Distinct Segments in r/r DLBCL Treatment Options Current r/r DLBCL U.S. Market 2L+ treatment choice based on efficacy, safety and accessibility in context of 2L Complex therapies Broadly accessible therapies ~65% individual patient need ~12k patients ~35% ~10% Bispecifics ADCs, mAbs, Chemo / oth
Slide 10: ZYNLONTA Combinations Potentially Raising the Bar on Efficacy in r/r DLBCL
ZYNLONTA Combinations Potentially Raising the Bar on Efficacy in r/r DLBCL 78% CR Complex LOTIS-7 (ZYNLONTA + glofitamab) Opportunity Therapies → We believe LOTIS-7 has the potential to be the leading bispecific combination regimen for patients with access to complex therapies → Leading CR rate that
Slide 11: ZYNLONTA Has Potential to Disrupt r/r DLBCL Market and Unlock Significant Growth Opportunity
ZYNLONTA Has Potential to Disrupt r/r DLBCL Market and Unlock Significant Growth Opportunity in Both Segments Complex therapies Broadly accessible therapies (CAR T-cell therapy, Bispecifics) (ADCs, mAbs, Chemo / other) 100 - 50 - Complete Response Rate (%) Complete Response Rate (%) 50% LOTIS-5 (Lon
Slide 12: LOTIS-5 Provides an Opportunity to Further Differentiate ZYNLONTA
LOTIS-5 Provides an Opportunity to Further Differentiate ZYNLONTA vs R-based Chemo and Other Broadly Accessible Therapies LOTIS-5 clinical profile builds on 2L indication significantly increases ZYNLONTA’s strengths peak revenue opportunity ZYNLONTA- ZYNLONTA-mono ZYNLONTA-R ZYNLONTA-R Assumptions C
Slide 13: 4Q 2025 Selected Financial Data
4Q 2025 Selected Financial Data Balance Sheet December 31, 2025 Cash and cash equivalents ($M) 261.3 Statement of Operations 4Q 2025 ($M) 4Q 2024 ($M) YoY % Product Revenues, Net 22.3 16.4 36.2 Total Revenue 23.1 16.9 36.4 Total Operating Expenses 41.0 49.3 -17.0 Adjusted Total Operating Expenses (N
Slide 14: Upcoming Expected Milestones
Upcoming Expected Milestones 1H2026 2H2026 1H2027 2H2027 Full enrollment of 100 pts at Publication and potential LOTIS- ZYNLONTA selected dose 7 compendia LOTIS-7 Generate additional data and assess regulatory and compendia strategies Potential confirmatory ZYNLONTA Share topline approval in 2L+ DLB
Slide 15: Thank You
Thank You ® THERAPEUTICS Innovating Science. Inspiring Hope.